NOVOCURE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.05 USD | -3.29% |
|
-17.58% | -19.29% |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the Novocure Q1 2022 ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
12.05
USD
Average target price
26.17
USD
Spread / Average Target
+117.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.29% | 1.3B | |
| +71.86% | 12.28B | |
| -17.04% | 8.08B | |
| +16.56% | 7.23B | |
| -4.77% | 5.29B | |
| +4.25% | 4.93B | |
| +17.19% | 4.19B | |
| -20.66% | 4.13B | |
| -40.39% | 2.24B | |
| +0.50% | 2B |
- Stock Market
- Equities
- NVCR Stock
- News NovoCure Limited
- Transcript : NovoCure Limited, Q1 2022 Earnings Call, Apr 28, 2022
